Christopher U Missling, PhD is President and CEO of Anavex Life Sciences, has over 20 years of healthcare industry experience within large pharmaceutical and biotech industry. Prior to joining Anavex, he served as Officer at Curis and ImmunoGen and previously at Aventis (now Sanofi). Christopher’s work is dedicated to finding potential cures for rare neurodevelopmental diseases, like Rett syndrome, autism spectrum disorder as well as degenerative diseases like Alzheimer’s and Parkinson’s disease by utilizing precision medicine. Dr. Missling is working with his team to advance new potential treatments through clinical trials involving the respective patient’s advocacy groups. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU.